Amgen Inc.

Symbol: AMG.DE




Market price today

  • 19.0593

    P/E Ratio

  • -1.1432

    PEG Ratio

  • 134.01B

    MRK Cap

  • 0.03%

    DIV Yield

Amgen Inc. (AMG-DE) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers—General
CEO:Mr. Robert A. Bradway
Full-time employees:25200
City:Thousand Oaks
Address:One Amgen Center Drive

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

General Outlook

In simple terms, Amgen Inc. has 535.178 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.736% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.337%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.282%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.084% return, is a testament to Amgen Inc.'s adeptness in optimizing resource deployment. Amgen Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 1.291%. Furthermore, the proficiency of Amgen Inc. in capital utilization is underscored by a remarkable 0.123% return on capital employed.

Stock Prices

Amgen Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $249.4, while its low point bottomed out at $246.8. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Amgen Inc.'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of Amgen Inc. (AMG.DE) on the XETRA in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is 19.059 in 2023.

What is the ticker symbol of Amgen Inc. stock?

The ticker symbol of Amgen Inc. stock is AMG.DE.

What is company IPO date?

IPO date of Amgen Inc. is 2000-01-03.

What is company current share price?

Current share price is 250.400 EUR.

What is stock market cap today?

The market cap of stock today is 134008571200.000.

What is PEG ratio in 2023?

The current -1.143 is -1.143 in 2023.

What is the number of employees in 2023?

In 2023 the company has 25200.